Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Brexpiprazole
Drug ID BADD_D00293
Description Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the treatment of schizophrenia, and as an adjunctive treatment for major depressive disorder (MDD). Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Indications and Usage As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
Marketing Status Prescription
ATC Code N05AX16
DrugBank ID DB09128
KEGG ID D10309
MeSH ID C000591922
PubChem ID 11978813
TTD Drug ID D0P0OU
NDC Product Code 59148-038; 59651-328; 46602-0036; 65129-1401; 46602-0039; 59148-040; 59148-035; 46602-0037; 46602-0038; 59148-039; 59148-036; 76055-0040; 46708-911; 46602-0040; 59148-037; 69766-041; 46602-0035; 65372-1201; 69037-0035; 53747-084
Synonyms brexpiprazole | 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one | Rexulti
Chemical Information
Molecular Formula C25H27N3O2S
CAS Registry Number 913611-97-9
SMILES C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.002709%Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Aggression19.05.01.0010.001806%Not Available
Agitation19.06.02.001; 17.02.05.0120.004515%
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.0020.029498%
Amnesia19.20.01.001; 17.03.02.001--
Anger19.04.02.0010.002408%Not Available
Anxiety19.06.02.0020.011137%
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Binge eating19.09.01.0010.001204%Not Available
Blood cortisol decreased13.10.09.004--Not Available
Blood creatine phosphokinase increased13.04.01.0010.001204%
Blood glucose increased13.02.02.0020.004816%Not Available
Blood pressure increased13.14.03.005--Not Available
Blood prolactin increased13.10.03.002--Not Available
Blood sodium decreased13.11.01.0120.000602%Not Available
Bradycardia02.03.02.002--Not Available
Catatonia19.11.01.0010.000602%Not Available
Cellulitis11.02.01.001; 23.09.01.0010.000602%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000550%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.000903%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages